首页> 外文期刊>Drug development and industrial pharmacy >Quality risk analysis in a cGMP environment: multiple models for comprehensive failure mode identification during the computer system lifecycle
【24h】

Quality risk analysis in a cGMP environment: multiple models for comprehensive failure mode identification during the computer system lifecycle

机译:cGMP环境中的质量风险分析:用于在计算机系统生命周期中进行全面故障模式识别的多种模型

获取原文
获取原文并翻译 | 示例
           

摘要

Pharmaceutical quality systems use various inputs to ensure product quality and prevent failures that might have patient consequences. These inputs are generally data from failures that have already occurred, for example process deviations or customer complaints. Risk analysis techniques are well-established in certain other industries and have become of interest to pharmaceutical manufacturers because they allow potential quality failures to be predicted and mitigating action taken in advance of their occurring. Failure mode and effects analysis (FMEA) is one such technique, and in this study it was applied to implement a computerized manufacturing execution system in a pharmaceutical manufacturing environment. After introduction, the system was monitored to detect failures that did occur and these were analyzed to determine why the risk analysis method failed to predict them. Application of FMEA in other industries has identified weaknesses in predicting certain error types, specifically its dependence on other techniques to model risk situations and its poor analysis of non-hardware risks, such as human error, and this was confirmed in this study. Hierarchical holographic modeling (HHM), a technique for identifying risk scenarios in wide-scope analyses, was applied subsequently and identified additional potential failure modes. The technique for human error rate prediction (THERP) has previously been used for the quantitative analysis of human error risk and the event tree from this technique was adapted and identified further human error scenarios. These were input to the FMEA for prioritization and mitigation, thereby strengthening the risk analysis in terms of failure modes considered.
机译:药品质量体系使用各种输入来确保产品质量并防止可能对患者造成后果的故障。这些输入通常是来自已经发生的故障的数据,例如过程偏差或客户投诉。风险分析技术在某些其他行业中已广为接受,并已引起制药商的关注,因为它们可以预测潜在的质量故障并在故障发生之前采取缓解措施。失效模式和影响分析(FMEA)就是这样一种技术,在这项研究中,它被用于在制药生产环境中实现计算机化的生产执行系统。引入后,将对系统进行监视以检测确实发生的故障,并对这些故障进行分析,以确定为什么风险分析方法无法预测这些故障。 FMEA在其他行业中的应用已发现在预测某些错误类型方面存在弱点,特别是在依赖其他技术来建模风险情况以及对非硬件风险(例如人为错误)的分析能力较差的情况下,这项研究得到了证实。随后应用了分层全息建模(HHM)(一种在广域分析中识别风险情景的技术),并识别了其他潜在的故障模式。先前将人为错误率预测技术(THERP)用于人为错误风险的定量分析,并且对该技术的事件树进行了调整并确定了其他人为错误场景。将这些输入到FMEA进行优先级排序和缓解,从而根据考虑的故障模式加强风险分析。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号